
Opinion|Videos|August 28, 2024
Impact of GnRH Agonists and Antagonists on Cardiovascular Outcomes in Prostate Cancer
Stephen Freedland, MD, discusses the role of GnRH agonists and antagonists on improving cardiovascular outcomes in patients with prostate cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What insights do data show regarding GnRH agonists and GnRH antagonists and cardiovascular outcomes? If a patient has prior CVD, should they be treated with a GnRH antagonist?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5















